Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
kondrium f
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Intra-articular Injection
01
Overview
Kondrium f is a pharmaceutical formulation developed for the treatment of osteoarthritis, specifically osteoarthritis of the knee. It is administered as an intra-articular injection and was evaluated in clinical trials alongside other formulations such as Kondrium (75 mg/mL) and methylprednisolone (8 mg/mL). The specific active ingredient(s) or detailed composition of Kondrium f are not disclosed in publicly available sources, but it is distinct from both standard Kondrium and methylprednisolone. Its primary mechanism appears to be related to symptomatic relief in osteoarthritis, assessed by validated indices such as WOMAC and Lequesne’s functional index[5][1][2].
- Brand names
- kondrium f
- Other names
- kondriumf
Beyond the preview
Go deeper on kondrium f.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on kondrium f.